Rasagiline (Azilai)’s Effect on the Liver and Safety Assessment

Rasagiline (trade name: Azilect) is a selective, irreversible inhibitor of monoamine oxidaseB (MAO-B). It is mainly used for early monotherapy and combined treatment with levodopa for Parkinson's disease (PD). By inhibiting MAO-B, rasagiline can prolong the action of central dopamine, improve motor symptoms and delay disease progression. As an oral small molecule drug, its metabolism is mainly carried out in the liver, so the impact on liver function and safety assessment are particularly important.

Rasagiline is mainly metabolized by the liver's CYP1A2 enzyme, and its metabolites are excreted in the urine. Clinical studies have shown that the liver function indicators of the vast majority of patients remain normal after taking rasagiline, but a small number of patients may experience mild elevations in aminotransferases (ALT/AST) or mild abnormalities in liver function. Cases of severe liver injury are rare, but caution is needed in patients with preexisting liver disease or hepatic impairment.

Overall, rasagiline was well tolerated. Common adverse reactions include Headache, joint pain, indigestion and insomnia, and the incidence of serious liver damage is extremely low. For patients with hepatic insufficiency, doctors usually decide whether to use it after assessing the risk, and recommend regular monitoring of serum aminotransferase and bilirubin levels. If a significant increase is found, the drug should be discontinued or the dose should be adjusted to avoid further deterioration of liver function.

In clinical applications, patients should undergo liver function tests before starting rasagiline treatment and inform their doctors of their past liver history. Liver function indicators should be reviewed regularly during treatment, especially when combined with other liver metabolism drugs. If patients develop abnormal symptoms such as jaundice, persistent fatigue, loss of appetite, or dark urine , they should seek medical treatment promptly. Through standardized monitoring and timely intervention, rasagiline can improve the symptoms of Parkinson's disease while its potential risks to the liver can be effectively managed.

Reference link:https://www.drugs.com